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Biochemical consequences of two 
clinically relevant ND‑gene 
mutations in Escherichia coli 
respiratory complex I
Franziska Nuber1, Johannes Schimpf1, Jean‑Paul di Rago2, Déborah Tribouillard‑Tanvier2, 
Vincent Procaccio3, Marie‑Laure Martin‑Negrier4,5,6*, Aurélien Trimouille4,7, Olivier Biner8,9, 
Christoph von Ballmoos8 & Thorsten Friedrich1*
NADH:ubiquinone oxidoreductase (respiratory complex I) plays a major role in energy metabolism by 
coupling electron transfer from NADH to quinone with proton translocation across the membrane. 
Complex I deficiencies were found to be the most common source of human mitochondrial dysfunction 
that manifest in a wide variety of neurodegenerative diseases. Seven subunits of human complex I 
are encoded by mitochondrial DNA (mtDNA) that carry an unexpectedly large number of mutations 
discovered in mitochondria from patients’ tissues. However, whether or how these genetic aberrations 
affect complex I at a molecular level is unknown. Here, we used Escherichia coli as a model system to 
biochemically characterize two mutations that were found in mtDNA of patients. The  V253AMT‑ND5 
mutation completely disturbed the assembly of complex I, while the mutation  D199GMT‑ND1 led to 
the assembly of a stable complex capable to catalyze redox‑driven proton translocation. However, 
the latter mutation perturbs quinone reduction leading to a diminished activity.  D199MT‑ND1 is part 
of a cluster of charged amino acid residues that are suggested to be important for efficient coupling 
of quinone reduction and proton translocation. A mechanism considering the role of  D199MT‑ND1 for 
energy conservation in complex I is discussed.
Mitochondria are essential organelles best known as powerhouses of the cell. The universal energy currency 
adenosine triphosphate (ATP) is produced in mitochondria via oxidative phosphorylation (OXPHOS), a process 
that couples electron transfer with ATP synthesis at the inner mitochondrial membrane. The electron transfer 
activities of complexes I to IV establish a protonmotive force (pmf) across the membrane that drives ATP syn-
thesis by the ATP synthase. Complexes I (NADH:ubiquinone oxidoreductase) and II (succinate:ubiquinone 
oxidoreductase) reduce ubiquinone (Q) by oxidizing NADH and succinate, respectively. The reduced ubiquinol 
 (QH2) is oxidized by complex III (cytochrome bc1) that in turn transfers the electrons to cytochrome c in the 
intermembrane space. Complex IV (cytochrome c oxidase), finally, accepts electrons from cytochrome c to reduce 
oxygen to water. The energy released during the electron transfer reactions is conserved by pumping protons 
from the mitochondrial matrix into the intermembrane space, thus generating the  pmf1–5.
Complex I couples NADH oxidation and Q reduction with the translocation of protons across the membrane. 
It has a two-part structure with a peripheral arm catalyzing the electron transfer reaction and a membrane arm 
conducting proton  translocation6–10. Mammalian complex I is made up of 45 subunits with 14 of them repre-
senting the core subunits required for catalytic activity. These 14 subunits are conserved between all species 
containing an energy-converting NADH:ubiquinone oxidoreductase and includes the seven subunits encoded 
by mitochondrial DNA (mtDNA) in humans.
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OXPHOS defects are the most common inborn errors of metabolism most frequently associated with a dys-
function of complex  I11. The deficiencies are genetically and clinically highly diverse including manifestations 
in early-onset neurodegenerative disorders such as mitochondrial encephalomyopathy and Leigh syndrome as 
well as lactic acidosis and  cardiomyopathy12. As seven subunits of human complex I are encoded by mtDNA, 
mutations with an impact on structure and function of complex I may occur in both, the mitochondrial and the 
nuclear  genome3,13–16. Complex I deficiencies caused by mutations in mtDNA are further influenced by their 
levels of heteroplasmy (i.e. the proportion of mutated vs wild type mtDNA) that show strong variations between 
patients cells and  tissues17–20.
Modern next-generation sequencing techniques allow to readily obtain sequence data from patients suffering 
from mitochondrial diseases and lead to a steadily increasing number of identified pathological  mutations21. 
However, biochemical data are mandatory to determine the impact of single mutations on the protein. These 
studies are complicated by the low amount of material available obtained by biopsy and from human cell 
 lines19,22,23. Instead, well-characterized model systems such as Escherichia coli, Paracoccus denitrificans, and Yar-
rowia lipolytica have been established to identify effects of specific mutations on stability, assembly and electron 
transfer activity of complex  I24–29. Although eukaryotic systems are evolutionary closer to the human enzyme, 
bacterial systems have the inestimable advantage that mutations found in mtDNA can be readily introduced 
into the bacterial genome. Protocols for mtDNA manipulation of the eukaryotic model organism Saccharomyces 
cerevisiae are available, but this organism does not possess respiratory complex I. As the architecture of the core 
subunits of complex I is conserved from bacteria to mammals, the structural minimal form of the E. coli enzyme 
was here used as model system. It has to be taken into account that E. coli lacks the so-called supernumerary 
subunits that stabilize mitochondrial complex I. This might influence the phenotype of a distinct mutation in 
the enzyme’s core structure. However, none of the positions studied here interact directly with a supernumer-
ary subunit excluding such a specific effect. E. coli complex I is made up of 13 different subunits encoded by 
the nuo-genes that add up to a molecular mass of approximately 550  kDa30,31. In our experimental setup, the 
nuo-genes are expressed from a plasmid in a nuo null strain facilitating their mutation. An efficient and straight 
forward purification strategy was established allowing thorough analysis of the variant enzymes regarding their 
assembly, stability and catalytic  activity32–36.
Here, we investigated the effect of two mutations that were identified in mtDNA of patients in the hospital 
center at the Centre Hospitalo-Universitaire de Bordeaux (Supplementary Text). A baby harboring the mutation 
m.13094T>C suffered from Leigh  syndrome37,38. The mutation leads to a replacement of a conserved valine 
residue by an alanine residue  (V253AMT-ND5) on subunit ND5. The second patient, an adult person suffering 
from nephropathy, deafness and diabetes mellitus carried an inversion of 7 bps (m.3902-3908inv7) in ND1. This 
inversion leads to the triple mutation D199G/L200K/A201VMT-ND139–41, of which only  D199MT-ND1 is conserved. 
We separately introduced the mutations at the conserved positions into a plasmid carrying the E. coli complex I 
genes and characterized the resulting mutant strains and the purified variants. The  V253AMT-ND5 mutation 
strongly disturbed the assembly leading to the production of an inactive and instable complex. The  D199GMT-ND1 
mutation resulted in the production of a stable variant that showed a decreased electron transfer activity coupled 
to proton translocation. Remarkably, the variant exhibited a pronounced activation kinetics indicating perturbed 
quinone chemistry. Interestingly enough,  D199MT-ND1 that is located between the two arms of the complex, is 
part of a cluster of charged residues that connects the quinone headgroup with the so-called E-channel that is 
discussed to play an essential role in proton  translocation42.
Results
Conservation of amino acid residues. Conservation of positions  D199MT-ND1 and  V253MT-ND5 that were 
found mutated in the patients was confirmed by multiple sequence alignment using more than 50 sequences of 
prokaryotic and eukaryotic species (a selection is shown exemplarily in Supplementary Fig. 1). The alignment 
shows that position  D199MT-ND1 is homologous to  D213H in E. coli and  V253MT-ND5 to  V259L (the superscript 
refers to the name of the subunit of E. coli complex I). Hereafter, the E. coli nomenclature is used for clarity.
NADH is oxidized by FMN at the top of the peripheral arm and the electrons are transferred towards the 
membrane by a series of seven iron-sulfur clusters (Fig. 1). The distal cluster reduces Q in a unique cavity 
composed of subunits of both arms including NuoH. Together with NuoA, J and K, NuoH builds the so-called 
E-channel, a putative proton channel that is connected to the quinone binding site by a cluster of charged and 
polar amino acid  residues42,43.  D213H is part of this cluster (Fig. 1). The chemistry of quinone reduction trig-
gers proton translocation in the membrane arm through a series of four putative proton channels by a so far 
poorly understood  mechanism44. NuoL is the most distal subunit of the membrane arm and harbors one of 
the proposed proton channels (Fig. 1).  V259L is located in TM helix 8 in close proximity to but not within the 
proposed proton  channel43.
Generation of mutants. The point mutations  V259AL and  D213GH were individually introduced into 
the pBADnuoHis expression plasmid encoding the entire E. coli nuo-operon under the control of the induc-
ible  PBAD arabinose promoter. Potential recombination with the chromosomal wild-type allele during cloning 
was excluded using strain DH5α∆nuo as cloning  host45. The expression strain BW25113∆ndh nuo:nptII_FRT 
was transformed with expression plasmids either encoding the parental genes or those with the mutation. The 
expression strain chromosomally lacks the gene of the alternative NADH dehydrogenase (ndh)46 and the nuo-
operon encoding complex I is replaced with the resistance cartridge (nptII) by λ-Red mediated  recombination35. 
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Figure 1.  Structure of complex I from human (A) and from T. thermophilus (B) (PDB:  5XTD81 and  6I0D82). 
For simplicity, subunits and residues of the bacterial complex are named according to the E. coli nomenclature. 
The positions of the mutations are shown in red; a close-up of the positions environment is shown in the insets. 
Residues of the area of charged amino acids around  D199MT-ND1/D213H and of the E-channel are shown in the 
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Growth curves. The strains were grown in minimal medium using acetate as non-fermentable carbon 
source. Under this condition, fast growth of E. coli to high OD values depends on the presence of a functional 
complex I to maintain its NADH/NAD+ ratio low which is essential for preserving the TCA  cycle35. As expected, 
the strain producing parental complex I grew the fastest, while the strain lacking both membranous NADH 
dehydrogenases showed the slowest growth rate (Fig. 2). Strains containing the plasmid grew faster than the 
double deletion strain even before induction due to a leaky expression (Fig. 2). The mutant strain producing 
the  D213GH variant grew as fast as the strain producing parental complex I, while the mutant strain containing 
the  V259AL variant entered the stationary growth phase shortly after induction of the extra-chromosomal nuo-
genes. Thus, the mutation on NuoL seems to significantly affect NADH oxidation by complex I, while this is not 
the case for the mutation on NuoH.
Activity of complex I and its variants in the cytoplasmic membrane. Cells were disrupted and 
cytoplasmic membranes were collected by differential  centrifugation47. The amount of complex I in the mem-
brane was estimated from the artificial NADH/ferricyanide oxidoreductase activity solely mediated by subunit 
NuoF containing the flavin  cofactor47. This reaction is not coupled with Q reduction and proton pumping. The 
 D213GH mutant strain showed similar amounts of the variant protein as the parental strain producing complex 
I. The activity of the  V259AL mutant strain was halved indicating a decreased share of the variant protein in the 
membrane (Table 1). The physiological activity of the complex and the variants was determined by measuring 
oxygen consumption upon an addition of NADH (Fig. 3A). Here, the  QH2 produced by complex I in a rate-
limiting step is used to reduce oxygen to water by the quinol oxidases. Membranes from the  V259AL mutant 
strain showed no activity (Table 1). Thus, the NuoL mutant contained half of the amount of complex I compared 
to the parental strain but this variant was unable to catalyze the reduction of Q.
Membranes from the  D213GH mutant strain contained a functional complex I, but the apparent activity was 
decreased by a quarter (Fig. 3A, Table 1). Noteworthy, while the NADH oxidase activity of wild-type membranes 
started immediately after an addition of NADH, measurements with membranes from the  D213GH mutant strain 
showed a prominent lag-phase and the maximal turnover of 72% (compared to parental complex) was reached 
after approximately 1 min (Table 1; Fig. 3A). To examine whether the dissociation of the product  QH2 from the 
Figure 2.  Growth of deletion strain BW25113∆ndh nuo:nptII_FRT (red) and strains BW25113∆ndh nuo:nptII_
FRT/pBADnuoHis (black), BW25113∆ndh nuo:nptII_FRT/pBADnuo HisnuoF D213GH (blue) and BW25113∆ndh 
nuo:nptII_FRT/pBADnuo HisnuoF V259AL (green) in minimal medium with acetate as sole carbon source. The 
black arrow indicates the induction of gene expression after 3 h growth by an addition of 0.02% arabinose.
Table 1.  NADH oxidase and NADH/ferricyanide oxidoreductase activity of cytoplasmic membranes from E. 
coli wild type and mutant strains. Data were derived from three biological replicas; each replica was measured 




[U/mg] [%] [U/mg] [%]
WT 0.421 ± 0.010 100 ± 2 2.00 ± 0.04 100 ± 2
V259AL 0.013 ± 0.002 3 ± 17 0.97 ± 0.09 50 ± 9
D213GH 0.302 ± 0.020 72 ± 7 1.88 ± 0.34 96 ± 18
5
Vol.:(0123456789)
Scientific Reports |        (2021) 11:12641  | https://doi.org/10.1038/s41598-021-91631-3
www.nature.com/scientificreports/
complex was hampered in the mutant, the quinone pool was partially reduced by complex II due to an addition 
of succinate before complex I activity was initiated by an addition of NADH. A more reduced Q pool is expected 
to prolong the duration of the lag-phase. However, the prior addition of succinate had no significant effect on 
the duration and the course of the NADH-induced lag-phase indicating that product release is not disturbed in 
the mutant (Fig. 3B and see below).
Assembly and stability of the variants. The stability of the complex and the variants in detergent 
was investigated by sucrose gradient density centrifugation (Fig.  4). Cytoplasmic membranes of cells grown 
in rich medium were incubated with DDM and the cleared extract was loaded onto a sucrose gradient. Solubi-
lized membrane proteins were separated by centrifugation and the gradients were fractioned in 1 mL portions. 
NADH/ferricyanide oxidoreductase activity of each fraction was determined showing that wild type complex 
sedimented around fraction 16 as described  earlier47. The activity profile of the gradient loaded with the extract 
from the  D213GH mutant strain was very similar: the peak was insignificantly broader and its position in the 
gradient within the experimental error. In contrast, no activity peak was detected in the gradient loaded with the 
extract from the  V259AL mutant strain (Fig. 4). To test whether a milder extraction could lead to an enrichment 
of the variant or an assembly intermediate, mutant membranes were treated with various low detergent concen-
trations and the NADH/ferricyanide oxidoreductase activity of the supernatant after high speed centrifugation 
was determined. It turned out that a substantial share of the activity was extracted with 0.2% DDM after 30 min 
(Supplementary Fig.  2). Accordingly, membrane extracts obtained after incubation with 0.2 and 0.8% DDM 
were loaded on a sucrose gradient as described above (Supplementary Fig. 2). However, at these mild conditions 
no activity peak from wild type complex I was detectable indicating that the DDM concentration was too low 
Figure 3.  Activity of complex I (black) and the  D213GH variant (blue). (A) NADH oxidase activity of the 
membranes, (B) NADH oxidase activity after partial reduction of the Q-pool by an addition of succinate 
(0.034 ± 0.001 U/mg protein). The maximum NADH oxidase activity of membranes from the wild type was 
0.413 ± 0.018 U/mg protein and that of membranes from the  D213GH mutant strain 0.194 ± 0.033 U/mg protein, 
(C,D) NADH:decyl-Q oxidoreductase activity of the preparations in the presence (C) and in the absence (D) of 
bo3 oxidase regenerating the quinol.
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to extract the complex from the membrane. Accordingly, no activity peak was observed in the gradients loaded 
with the 0.2 and 0.8% extract from the mutant membranes (Supplementary Fig. 2). The activity in the detergent 
extract most likely derived from the detached peripheral arm of the complex. The peripheral arm is not stable on 
its own and  decays47. Thus, the mutation  V259AL leads to an unstable complex that disintegrates upon detergent 
treatment. These findings are in line with the diminished NADH/ferricyanide oxidoreductase activity and the 
lack of NADH oxidase activity in this strain (Table 1).
Isolation of complex I and of the  D213GH variant. The complex was isolated from the parental strain 
and the  D213GH mutant strain grown in rich medium. Membrane proteins were extracted with the detergent 
LMNG and the complex was prepared to homogeneity by affinity- and size exclusion-chromatography (Fig. 5). 
In average, 7–9 mg protein was obtained from 50 g cells. Both preparations contained all complex I subunits as 
judged from SDS-PAGE and the protein band pattern of both preparations was virtually identical. The EPR spec-
tra of the variant showed no differences to that of the complex (Fig. 5). Concentrated samples of both prepara-
tions were abruptly diluted in buffer to determine their stability by mass  photometry48,49 (Supplementary Fig. 3). 
The molecular mass of the main peak in both samples was 733 kDa corresponding to complex I with bound 
detergent. This peak contained 77% of all binding events in both samples demonstrating that both preparations 
share the same stability. A decreased stability of the variant would result in a decreased number of binding events 
at that molecular mass.
Catalytic activities of the preparations. The preparations of complex I and the  D213GH variant had 
similar specific NADH/ferricyanide oxidoreductase activities of 100 ± 10 U/mg (Table 2). The  D213GH variant 
showed about half of the NADH:decyl-Q oxidoreductase activity of the parental complex with bo3 oxidase as 
a quinone regenerating system (Table 2). Again, the kinetic trace of the variant exhibited a slow initial velocity 
that accelerated over time as observed in the measurement with membranes (Fig. 3C). In the absence of the Q 
regenerating system,  QH2 is steadily enriched in the membrane. If the kinetic lag-phase of the variant is due to a 
disturbed release of the product, the lag-phase should be more pronounced in the absence of bo3 quinol oxidase. 
Under this condition, both preparations showed a much lower activity, however, the variant’s kinetic lag-phase 
remained unchanged (Fig. 3D). Thus, the mutation did neither influence NADH oxidation, nor the release of 
the product  QH2. EPR spectra of the Fe/S clusters remained unchanged indicating an intact electron transfer in 
the peripheral arm. This indicates that Q reduction, which requires proton uptake, is most likely affected by the 
mutation.
In order to measure NADH-driven proton translocation across membranes, the preparations of complex I 
and the  D213GH variant were reconstituted into preformed liposomes according to protocols established for bo3 
oxidase and ATP  synthase76. The orientation of the complex in proteoliposomes was estimated by measuring the 
NADH/ferricyanide oxidoreductase activity before and after an addition of 2% DDM. Both preparations showed a 
similar orientation with about 60% of the NADH binding site on the outside. Only these proteins are addressed in 
measurements as the substrate NADH is membrane impermeable. Proteoliposomes were incubated with decyl-Q 
for two minutes to allow its equilibration with the membrane. Proton pumping was initiated by the addition of 
130 µM NADH that leads to an acidification of the liposome lumen and a membrane potential ∆Ψ that is inside 
positive. First, acidification of the vesicles was followed using the 9-amino-6-chloro-2-methoxyacridine (ACMA) 
fluorescence quenching measurements (Fig. 6A). Upon addition of NADH, fluorescence is quenched in both 
preparations however, the rate obtained with proteoliposomes containing the variant was diminished to about 
50–70% depending on proteoliposome preparation. Importantly, the signals obtained with both preparations 
Figure 4.  Sucrose gradient of detergent solubilized membranes from wild type (black) and the  D213GH (blue) 
and  V259AL (green) mutant strains. The NADH/ferricyanide oxidoreductase activity of each fraction is shown; 
the activities are normalized to 20 mg membrane protein extract applied on each gradient.
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were sensitive to an addition of valinomycin, indicating that a counteracting membrane potential was built up 
during proton pumping. In addition, the delay in reaching maximal activity with the  D213GH variant was also 
observed in this type of measurement (Fig. 6B).
Generation of a membrane potential ∆Ψ (inside positive) was followed photometrically with the potential-
sensitive dye oxonol VI (Fig. 6C). The signal observed with proteoliposomes with the  D213GH variant showed 
approximately one third of the amplitude of that with complex I. Both signals were fully sensitive to addition 
of the ionophore valinomycin that abolishes ∆Ψ in the presence of potassium. These experiments show that the 
 D213GH variant is capable of catalyzing redox-driven electrogenic proton-translocation. The observed rates of 
proton translocation and generation of ∆Ψ are in accord with the decreased NADH:decyl-Q oxidoreductase 
activities measured with the solubilized enzymes, suggesting that the NADH/H+ stoichiometry is not affected. The 
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Figure 5.  Preparation of complex I and the  D213GH variant. Elution profile of (A) the affinity-chromatography 
on ProBond  Ni2+-IDA and (B) the size exclusion chromatography on Superose 6. Fractions indicated with a grey 
background were used in the next step. Preparations of the wild type and the variant showed virtually identical 
elution profiles. (C) SDS-PAGE of both preparations revealing the presence of all complex I subunits. The faint 
band at around 80 kDa is a proteolytic digestion product of NuoG. (D) EPR spectra of the preparation of the 
 D213GH variant reduced with NADH at 40 K and 2 mW (top), 13 K and 5 mW (bottom).
Table 2.  NADH:decyl-Q and NADH/ferricyanide oxidoreductase activity of complex I and the  D213GH 
variant in detergent. Data were derived from three biological replicas; each replica was measured in triplicates. 




[U/mg] [%] [U/mg] [%]
WT 41.0 ± 1.1 100 ± 3 94.0 ± 6.7 100 ± 7
D213GH 19.0 ± 1.4 46 ± 8 91.5 ± 5.6 97 ± 6
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strong sensitivity of proton pumping towards valinomycin supports the idea of an intact coupling mechanism. 
However, the observed delay in all measurements points towards hampered quinone reduction.
Discussion
The complex I mutations described here were previously identified as clinically  relevant37–41. The m.13094T>C 
mutation exhibits variable neurological manifestations and is associated with an early  mortality37,38 as with the 
patient reported here. This may be explained by the drastic effect of the  V259AL mutation in E. coli, namely a 
faulty assembly leading to a fragile and inactive complex I.  V259L is located in TM helix 8 in close proximity 
to a π-helix running from position 253 to  25843 and close to the most distal putative proton channel. π-Helices 
are commonly used to enhance protein  functionality50. It was proposed that the π-helix in NuoL is an essential 
element to structure its  core51. The stabilization of the protein structure is most likely disturbed by the muta-
tion resulting in the drastic effects. Accordingly, the patients suffer from an imbalanced NADH/NAD+ ratio 
in mitochondria that down regulates the Krebs  cycle52. Furthermore, the first coupling site in mitochondria is 
lost resulting in a decreased energy supply. These findings are in accordance with severe patient outcomes in 
childhood. Valente et al.53 reported data of cybrids derived from a child carrying the m.13094T>C mutation to 
a highly variable mutant load in skeletal muscle, lymphocytes and fibroblasts. The activity of complex I strongly 
correlated with the degree of heteroplasmy resulting in a nearly complete loss of complex I activity in cybrids 
that carry high mutant loads. The amount of complex I was clearly diminished in 80% heteroplasmic mutant 
cybrid cells and an assembly intermediate containing the membrane arm of the complex was accumulated in 
the  membranes53. Unfortunately, an assembly intermediate lacking NADH dehydrogenase activity cannot be 
detected by our assays.
It is remarkable that a single point mutation in NuoL leads to the disintegration of the entire complex. 
Recently, we have shown that a deletion of nuoL in E. coli results in the assembly of the entire complex just lack-
ing  NuoL54 while C-terminal truncations of NuoL were tolerated and led to the assembly of the entire  complex54. 
Thus, it is most likely that the central π-helix is an essential element to structure  NuoL51 and that the mutation 
induced NuoL misfolding or destabilization that is transmitted to the other subunits of the complex. It was 
Figure 6.  Generation of a pmf by E. coli complex I (black) and the  D213GH variant (red) reconstituted into 
liposomes. (A) Generation of a ΔpH measured as quench of the ACMA fluorescence. The reaction was started 
by addition of 130 µM NADH. Addition of valinomycin dissipates the Δψ and accelerates NADH turnover and 
proton pumping. Addition of 20 mM  NH4Cl dissipated the proton gradient. (B) Close-up of A to reveal the lag 
in proton pumping activity in the  D213GH mutant. (C) Generation of a ΔΨ measured as the decrease of the 
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also reported that single point mutations in NuoL (e.g.  R431L)55 and in NuoN (e.g. K217)56 fully disturbed the 
assembly of complex I.
The inversion of 7 bps on mitochondrial DNA (m.3902-3908inv7; MT-ND1) leads to a triple mutation on 
ND1 while maintaining the reading frame. One patient with the inversion found in several tissues such as heart, 
muscle and liver, died in  infancy40. The patient reported here has a heteroplasmy of 67% in muscle, 20% in buc-
cal epithelial cells and absent in blood. Other patients carry this mutation solely in  muscles39. A morphological 
and enzyme histochemical analysis of skeletal muscle biopsy from patient 2 is shown in Supplementary Fig. 4. 
These patients experienced symptoms such as exercise intolerance, myalgia, deafness and nephropathy in their 
40  s39. Only position D199 (human numbering) is conserved. Various other residues such as Phe, Gln and Asn 
are found at position L200 (human numbering). In position A201 (human numbering) Thr, Gln and even Pro are 
present. As D199 resides in a region with a high degree of sequence conservation, a change of all three amino acid 
residues in question might disturb the local structure. This structural effect might obscure the functional effect of 
the single  D199GMT-ND1 mutation that kept structural changes at a minimum. Furthermore, the triple mutation 
D199G/L200K/A201VMT-ND1changes the overall negative charge of the short stretch to a positive one. However, 
it cannot be excluded that there is an additional influence of the other mutations caused by the inversion.
The  D213GH mutation in E. coli led to the assembly of a stable variant capable to catalyze a diminished elec-
tron transfer coupled with proton translocation. Accordingly, the mutation  D199GMT-ND1 might have a milder 
effect in humans as it only slightly affects energy supply and the mitochondrial NADH/NAD+ ratio.
Mutations of E. coli residue  D213H were reported  earlier27,28. The exchange to either a glutamate or an aspara-
gine residue had little or no effects on the assembly of the complex but diminished its NADH:decyl-Q oxidore-
ductase activity by 60 and 40%,  respectively28. Interestingly,  D213EH, but not  D213NH showed also a lag-phase 
within the first minute of the measurement. In contrast, the  D213AH variant showed a disturbed assembly and 
a loss of 90% of the decyl-Q oxidoreductase  activity27. Nevertheless, oxidation of d-NADH, a substrate specific 
for complex I, led to the generation of a membrane potential although with smaller amplitude than in wild type.
We propose that the  D213GH and possibly also the  D213EH mutation influences quinone chemistry that 
drives proton translocation. According to computational and structural studies, the Q cavity provides at least 
two binding  positions5,43,44,51,57–62. Q binds in 12 Å distance to the distal iron-sulfur cluster, N2, approximately 
15 Å above the membrane  surface43,63. The quinone headgroup is hydrogen-bonded by two conserved residues, 
namely  Y273CD and  H224CD64,65. The human orthologues of NuoCD are two separated subunits called NDUFS3 
and NDUFS2, respectively. It is reasonable to assume that Q is sequentially reduced by electrons from cluster 
N2 and protonated by these two residues. A recently discovered water-channel leading to this position may be 
used to re-protonate the tyrosine and histidine  residues51. A hydrogen bond between  H224CD and  D325CD is 
broken upon deprotonation of  H224CD, leading to a conformational move of  D325CD towards an area of charged 
residues, allowing  QH2 to dissociate and move towards its second binding  site62,66 (Fig. 7).  QH2 movement may 
initiate proton  pumping42 by a change of dipolar interactions within the membrane arm as described in detail 
Figure 7.  Proposed mechanism to activate proton pumping in respiratory complex I. The structure of the 
quinone binding site with the cluster of charged amino acids and residues of the E-channel are shown (T. 
thermophilus complex I, PDB:  6I0D82). For clarity, residues are labeled according to the E. coli numbering. 
Q is bound close to iron-sulfur cluster N2 where it is reduced by N2 and protonated by  Y273CD and  H224CD. 
According to the proposed model, the product  QH2 moves to a second binding position in close vicinity to an 
area of charged amino acids, where it is deprotonated resulting in the formation of the  QH- anion, while the 
proton is transferred into the area of charged amino acids comprising  D213H. This proton transfer activates 
proton translocation as  described44 resulting in a surplus proton on an acidic amino acid of the E-channel 
after proton translocation. This proton is transferred to the  QH− anion leading to the formation of  QH2 that is 
released from the enzyme.
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by  Kaila44. The area of charged amino acid residues including  D213H connects the quinone binding site with the 
E-channel, the proton translocation pathway closest to the peripheral  arm42,43.
According to electrostatic calculations, the movement of  QH2 towards its second binding site may alter the 
protonation state of nearby titratable  residues42,60,66–68 possibly facilitating the deprotonation of  QH2 to the QHˉ 
anion that is discussed to be a relevant intermediate. We propose that upon movement of  D325CD, the cluster 
of charged amino acids acts as a putative proton relay system deprotonating  QH2 (Fig. 7). The extracted proton 
is transferred to the E-channel initiating a cascade of changing dipolar interactions that continues all along the 
membrane arm. According to the theory, the ‘wave’ of changing dipolar interactions is reflected at the end of the 
membrane arm and travels back towards the peripheral arm, leading to proton uptake from the N-side and to 
proton release to the P-side. This process ends with a surplus proton that might be localized on an acidic amino 
acid residue of the E-channel. According to our model, the QHˉ anion formed at the cluster of charged amino 
acids moves to the second Q binding site where it is re-protonated and  QH2 leaves the quinone binding cavity. 
From these considerations, it is obvious that the array of charged residues plays a crucial role both in the timing 
of proton coupled electron transfer and also in the efficient transfer of the anionic intermediate to the second 
binding site. Electron transfer and proton translocation activity of the  D213H variant showed a prominent lag-
phase in which activity accelerated over time (Figs. 3 and 6). The localization of  D213H suggests that electron 
and proton transfer to Q and initial displacement of  QH2 is unaffected also in the  D213GH variant. However, it 
can be envisioned that the mutation disturbs the finely tuned  pKA balance in the area of charged amino acids and 
either affects deprotonation of  QH2 or proton release to the E-channel. MD-simulations and cryo-EM structures 
show that the area of charged residues is  hydrated51,68, possibly enabling the insertion of a structural water at the 
mutated position  G213H, representing a poor but sufficient substitute for the carboxylate group. Accordingly, the 
pronounced lag-phase of activity would be caused by a slow hydratization of this position. This hydratization is 
not possible with the more voluminous alanine variant reported in the  literature27,28 leading to the pronounced 
inactivity. Hydratization is also not possible for the  D213EH and  D213NH mutants, but the hydrophilic nature 
of the side chains still allows for coupled reaction to occur.
A plethora of mtDNA mutations coding for complex I subunits are associated with the occurrence of mito-
chondrial disorders. Here, we applied a strategy to introduce clinically relevant mutations into bacterial complex 
I enabling the manipulation of genes that are mitochondrially encoded in eukaryotes. Other clinically relevant 
mutations with a mild patient outcome may lead to the identification of distinct changes that are helpful to clarify 
the mechanism of respiratory complex I.
Methods
Sequence alignments. Multiple Sequence Alignments were performed using ClustalX 2.169. Default val-
ues were used for the penalties for opening and extending gaps.
Strains, plasmids and oligonucleotides. A derivative of E. coli strain  BW2511370 chromosomally lack-
ing the gene ndh and in which the chromosomal nuo operon was replaced by a resistance cartridge (nptII)35 was 
used as host to overproduce complex I and its variants. E. coli strain DH5α∆nuo45 was used for site-directed 
mutagenesis. Oligonucleotides were obtained from Sigma-Aldrich (Supplementary Table  1). Restriction 
enzymes were obtained from Fermentas.
The plasmid pBADnuoHis32 was used to introduce the respective point mutations on nuoL and nuoH by 
site-directed mutagenesis according to the QuikChange protocol (Stratagene, La Jolla, CA, USA). Silent muta-
tions were introduced generating a new restriction site near by the point mutation to identify positive clones by 
restriction analysis. Primer pairs nuoL_V259A and nuoH_D213G (Supplementary Table 1) were used to gener-
ate the plasmids pBADnuo HisnuoF  D213GH and pBADnuo HisnuoF  V259AL. The PCR was performed using the 
KOD Hot Start DNA Polymerase (Novagen). Mutations were confirmed by DNA sequencing (GATC Eurofins, 
Konstanz, Germany).
Cell growth and isolation of cytoplasmic membranes. Strains were grown aerobically at 37 °C while 
agitating at 180 rpm. Minimal  medium71 with 25 mM acetate as sole carbon source and baffled flasks were used. 
After 3 h growth, expression of the nuo operon was induced by an addition of 0.02% (w/v) l-arabinose. For 
protein preparation, cells were grown in auto-induction  medium72 (1% (w/v) peptone, 0.5% (w/v) yeast extract, 
0.4% glycerol, 25 mM  Na2HPO4·2  H2O, 25 mM  KH2PO4, 50 mM  NH4Cl, 5 mM  Na2SO4, 2 mM  MgSO4·7H2O, 
0.2% (w/v) l-arabinose, 0.05% (w/v) glucose, 30 mg/L Fe-NH4-citrate, 0.5 mM l-cysteine, 50 mg  L−1 ribofla-
vin) containing chloramphenicol (34  µg/ml) and harvested by centrifugation (5700×g, 15  min, 4  °C; Avanti 
J-26 XP, Beckman Coulter; Rotor JLA 8.1000) in the exponential phase yielding between 6 and 7 g cells/L. All 
further steps were carried out at 4 °C. The cell sediment was suspended in a fivefold volume buffer A (50 mM 
MES/NaOH, 50 mM NaCl, pH 6.0) containing 0.1 mM PMSF supplemented with a few grains of DNAseI and 
disrupted by passing three times through an EmulsiFlex-C5 (1000–1500 bar). Cell debris was removed by cen-
trifugation (9500×g, 20 min, 4 °C; RC-5 Superspeed Refrigerated Centrifuge, Sorvall Instruments; Rotor A 8.24). 
Cytoplasmic membranes were obtained from the supernatant by ultra centrifugation (160,000×g, 60 min, 4 °C; 
LE-80K Ultrafuge, Beckman; Rotor 60 Ti). Sedimented membranes were suspended in an equal volume (1:1, 
w/v) buffer  A* (buffer A with 5 mM  MgCl2) containing 0.1 mM PMSF.
Electron transfer activity. Activity assays were performed at 30 °C. The NADH oxidase activity of cyto-
plasmic membranes was determined by a Clarke-type oxygen electrode (DW1, Hansatech) to monitor the 
decrease in oxygen concentration in the buffer. The electrode was calibrated by an addition of a few grains 
sodium dithionite to air saturated buffer. The difference before and after reduction was attributed to 237 mM 
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 oxygen73. The assay contained 5 µL cytoplasmic membranes (80–90 mg/mL) in 2 mL buffer A*. After equilibra-
tion, the reaction was started by an addition of 1.25 mM NADH. In order to partially reduce the Q-pool, the 
activity of complex II was initiated by adding 10 mM succinate. After three minutes complex I was activated by 
the addition of 1.25 mM NADH. The NADH/ferricyanide oxidoreductase activity was determined as decrease 
in the absorbance of ferricyanide at 410 nm with a diode-array spectrometer (QS cuvette, d = 1 cm, Hellma; 
TIDAS II, J&M Aalen) using an ε of 1  mM−1  cm−174. The assay contained 10 µL membrane suspension or 0.1 µL 
complex I and 1 mM  K3[Fe(CN)6] in buffer A*. The reaction was started by an addition of NADH (0.2 mM, final 
concentration). The NADH:decyl-Q oxidoreductase activity was measured as decrease of the NADH concentra-
tion at 340 nm using an ε of 6.3  mM−1  cm−1 (QS cuvette, d = 1 cm, Hellma; TIDAS II, J&M Aalen)75. The assay 
contained 60 µM decyl-Q, 2 µg complex I and a tenfold molar excess (5 µg) E. coli cytochrome bo3  oxidase77 (if 
appropriate) in buffer A*MNG (buffer A* with 10% (v/v) glycerol, 0.005% (w/v) LMNG (2,2-didecylpropane-1,3-
bis-β-d-maltopyranoside; Anatrace)). The reaction was started by an addition of 150 µM NADH.
Sucrose gradient centrifugation. Membrane proteins were extracted by an addition of 1% (w/v) DDM 
(n-Dodecyl-β-d-Maltoside; Anatrace) to a membrane suspension (80–90 mg/mL) in buffer A*. After incubation 
for 1 h at 4 °C, the suspension was centrifuged for 20 min at 160,000×g and 4 °C (Rotor 60Ti, L8-M Ultrafuge, 
Beckman). 1 mL of the supernatant was loaded onto 24 mL gradients of 5–30% (w/v) sucrose in A*DDM (buffer 
A* with 0.1% (w/v) DDM) and centrifuged for 16 h at 140,000×g (4 °C, Rotor SW28, L8-M Ultrafuge, Beckman). 
The gradients were fractionated into 1 mL aliquots and the NADH/ferricyanide oxidoreductase activities of each 
fraction was determined by following the decrease in ferricyanide absorbance at 410 nm with an Ultraspec spec-
trophotometer (Amersham Pharmacia Biotech, Munich, Germany)47. To determine the stability of the  V259AL 
variant, membranes (80 mg/mL) were incubated for 30 min at 4 °C with various DDM concentrations (0.1–1.0%; 
w/v), the suspension was centrifuged as described above and the NADH/ferricyanide activity of the supernatant 
was measured. According to the results, membrane proteins were extracted from the mutant membranes with 
0.2 and 0.8% (w/v) DDM and extracted proteins were separated by sucrose gradient centrifugation as described 
above.
Preparation of complex I and the variant. All steps were carried out at 4 °C as  described36. LMNG is a 
final concentration of 2% (w/v) was added to a membrane suspension (~ 70 mg/mL) in buffer A*pH6.8. After incu-
bation for 1 h at room temperature with gentle stirring, the suspension was centrifuged for 20 min at 160,000×g 
and 4  °C (Rotor 60Ti, L8-M Ultrafuge, Beckman). The supernatant was filtered (Filtropur S0.45; Sarstedt), 
diluted to 150 mL, adjusted to 20 mM imidazole and applied to a 35 mL ProBond  Ni2+-IDA column (Invitrogen) 
equilibrated in binding buffer (A*MNG with 20 mM imidazole and pH 6.8). The column was washed with bind-
ing buffer and subsequently with binding buffer containing 116 mM imidazole until the absorbance at 280 nm 
dropped below 500 mAu. Bound proteins were eluted with binding buffer containing 308 mM imidazole. Frac-
tions containing NADH/ferricyanide oxidoreductase activity were pooled and concentrated by ultrafiltration in 
100 kDa MWCO Amicon Ultra-15 centrifugal filter (Millipore). The concentrate was applied onto a Superose 
6 size exclusion chromatography column (300 mL, GE Healthcare) equilibrated in buffer  A*MNG. The fractions 
with highest NADH/ferricyanide oxidoreductase activity were pooled and concentrated as described above. The 
protein was either directly used or stored at − 80 °C.
Preparation of liposomes. E. coli’. polar lipids (25 mg/mL in  CHCl3; Avanti) were evaporated and dis-
solved in the fivefold volume lipid buffer (5 mM MES/NaOH, 50 mM NaCl, pH 6.7)76. The suspension was fro-
zen in liquid nitrogen and thawed at 29 °C seven times to get unilamellar vesicles. The liposomes were extruded 
by at least 21 passes through an extruder (0.1 µM polycarbonate membrane, Mini Extruder; Avanti). For recon-
stitution, ~ 0.5 mg complex I was mixed with reconstitution buffer (1:3; v/v) (10 mM Bis–tris-propane/MES, 
100 mM KCl, 73 mM sucrose, 2.5 mM  MgSO4, 0.05% (w/v) l-α-phosphatidylcholine, 1.1% (w/v) n-octylglu-
coside, 0.6% (w/v) sodium deoxycholate, 0.6% (w/v) sodium cholate, pH 7.5) and incubated for 5 min on ice. 
250 µL liposomes were mixed with 8 µL sodium cholate (20%, w/v) and the liposomes and complex I in recon-
stitution buffer were mixed and incubated for 20 min at room temperature with occasional flicking of the tube. 
Liposomes were formed using a size exclusion column (PD-10 Desalting Column, 8.3 mL, Sephadex G-25, GE 
Healthcare) equilibrated in lipid buffer to remove excess detergent. The eluate (1.2 ml) was centrifuged (4 °C, 
200,000×g, 45 min) and sedimented proteoliposomes were gently re-suspended in 500 µL lipid buffer.
Membrane potential and proton gradient. The generation of ∆pH was determined by monitoring 
the fluorescence quenching of the pH sensitive dye 9-amino-6-chloro-2-methoxyacridine (ACMA, Sigma). The 
assay contained 100 µM decyl-Q (Sigma), 0.2 µM ACMA and 50 µL proteoliposomes in ACMA buffer (10 mM 
Bis–tris-propane/MES, pH 6.75, 100 mM KCl and 2 mM  MgCl2). The reaction was performed at 25  °C and 
started by addition of 200 µM NADH. The fluorescence was detected with a Cary Eclipse fluorescence spectrom-
eter (Agilent), using excitation and emission wavelengths of 410 nm and 480 nm, respectively. An addition of 
20 mM  NH4Cl was used to dissipate the ∆pH.
The generation of ∆Ψ was determined by monitoring the changes in absorption of the potential-sensitive dye 
oxonol VI (Sigma). The assay contained 1 µM oxonol VI, 50 µM decyl-Q and proteoliposomes in oxonol buffer 
(10 mM MES/KOH, pH 6.75, 2 mM  MgSO4, 100 mM KCl, 10 mM  NH4Cl)76. The reaction was performed at 
25 °C and started by addition of 100 µM NADH. The absorbance at 590–623 nm was measured with a diode-
array spectrometer (QS cuvette, d = 1 cm, Hellma; TIDAS II, J&M Aalen). An addition of 200 nM valinomcyin 
was used to dissipate ∆Ψ.
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Other analytical procedures. Protein concentration was determined according to the biuret method 
using BSA as a  standard78. The concentration of purified complex I was determined by the difference of absorb-
ance at 280–310  nm (TIDAS II, J&M Aalen) using an ε of 781   mM−1   cm−1 as derived from the amino acid 
 sequence79. SDS-PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis) was performed according 
to Schägger80 with a 10% separating gel and a 3.9% stacking gel. EPR spectra were recorded at 40 and 13 K with 
a Bruker EMX 6/1 spectrometer operating at X-band33. The samples were reduced by an addition of 1.000-fold 
molar excess NADH and a few grains of dithionite. Mass photometry was measured with a OneMP (Refeyn) as 
 described48,49. One µL of a concentrated sample (1 µM) of the preparations of complex I and the  D213GH variant 
were diluted with A*MNG buffer to 50 nM on the cover slip and after autofocus stabilization, movies of 60 s dura-
tion were recorded. Data were acquired with AcquireMP (Refeyn Ltd., v.1.2.1).
Data availability
The source data underlying Figs. 2, 3, 4, 5, 6 are provided as a Source Data file. Other data are available from the 
corresponding authors upon reasonable request.
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